A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer

NCT01062620 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
49
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Axelar AB